Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01968083
Completed
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
Gender:
ALL
Ages:
Between 6 months and 24 months
Trial Updated:
07/19/2021
Locations: University of California, UC San Diego CRS, La Jolla, California +4 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
NCT02593227
Completed
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2021
Locations: Moffitt Cancer Center, Tampa, Florida +10 locations
Conditions: Breast Cancer
Register for Updates
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
NCT04444284
Completed
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as drops in the nose. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 15 and 59 months who are seropositive to RSV.
Gender:
ALL
Ages:
Between 15 months and 59 months
Trial Updated:
06/26/2021
Locations: Meridian Clinical Research, Norfolk, Nebraska +2 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine
NCT04094883
Completed
The purpose of this study is to test whether the group B meningitis vaccine (brand name Bexsero™) induces immune responses against the bacteria that causes gonorrhea. Participants: Approximately 15 Individuals who are 18-25 years of age that are not pregnant, HIV negative, have no history of congenital immunologic disorder, and are not taking immune suppressive medications will be enrolled on this study at a single site, University of North Carolina at Chapel Hill (UNC-CH). Procedures (methods... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
06/24/2021
Locations: University of North Carolina Health Care, Chapel Hill, North Carolina
Conditions: Neisseria Gonorrhoeae Infection
Register for Updates
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
NCT04762511
Terminated
The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/24/2021
Locations: GSK Investigational Site, Lenexa, Kansas +1 locations
Conditions: Herpes Simplex
Register for Updates
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
NCT02544880
Completed
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune response and promote a permissive environment that should increase the efficacy of anti-tumor vaccine in a setting of minimal residual disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2021
Locations: University of Miami, Miami, Florida
Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Vaccination of Advanced-Stage Lung Cancer Patients
NCT02264236
Withdrawn
The overarching purpose of this study is to evaluate the clinical efficacy of an investigational agent, P10s-PADRE, a peptide mimotope-based vaccine, in combination with standard-of-care (SoC) treatment in subjects with advanced-stage (i.e., metastatic) Lung Cancer. Vaccine will consist of P10s-PADRE admixed with an adjuvant, MONTANIDETM ISA 51 VG. Up to one hundred fifty (150) subjects with advanced-stage Lung Cancer of any histologic type will be enrolled for this vaccine trial. This single-a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/08/2021
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Lung Neoplasms
Register for Updates
HPV Centralized R/R RCT #2 - New York State
NCT03294551
Completed
The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379. Due to some changes in study design, protocol, and cohort of interest, a new registration was warranted. The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness, and sustainability of utilizing statewide immunization information systems (IISs) to conduct centralized reminder recall (R/R) to improve human papillomavirus (HPV) v... Read More
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
05/26/2021
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Vaccines
Register for Updates
Pediatric Second Influenza Dose Portal Reminder Recall
NCT04668417
Completed
This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. The study design is a parallel 2-arm trial. The parallel arms are 1) a reminder letter for the second dose of influenza vaccine (reminder messages sent via the patient portal) with a direct appointment scheduling link included in the reminder and 2) a reminder letter for the second dose of influenza vaccine, but no direct appointment scheduling link included.
Gender:
ALL
Ages:
Between 6 months and 36 months
Trial Updated:
05/26/2021
Locations: University of California LA, Los Angeles, California
Conditions: Influenza, Respiratory Tract Infections
Register for Updates
Age and Response to Flu Vaccines
NCT03328325
Completed
The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline, day 7, 28 and 90. The primary objective of... Read More
Gender:
ALL
Ages:
Between 9 years and 99 years
Trial Updated:
04/29/2021
Locations: Rochester General Hospital - Infectious Disease Unit, Rochester, New York +1 locations
Conditions: Influenza, Influenza Immunisation
Register for Updates
Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
NCT00787826
Unknown
This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2021
Locations: U.S. Army Medical Research Institute of Infectious Diseases, Fort Deterick, Maryland
Conditions: Tularemia
Register for Updates
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
NCT03481816
Completed
Background: Metastatic castration resistant prostate cancer (mCRPC) keeps growing even when the amount of testosterone in the body is reduced to very low levels. mCRPC is incurable. Researchers want to develop vaccines to teach the immune system to target and kill cancer cells. They want to test three of these vaccines (ETBX-071, ETBX-061, and ETBX-051) against mCRPC. Objective: To test the safety of combination ETBX-071, ETBX-061, and ETBX-051 and to study their effects on the immune system.... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostatic Cancer
Register for Updates